Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

227

Participants

Timeline

Start Date

April 12, 2024

Primary Completion Date

September 28, 2027

Study Completion Date

May 15, 2028

Conditions
Advanced Solid Tumor
Interventions
DRUG

BG-C9074

administered by intravenous infusion

DRUG

Tislelizumab

administered by intravenous infusion

Trial Locations (35)

10408

NOT_YET_RECRUITING

National Cancer Center (Korea), IlsandongGu GoyangSi

13496

NOT_YET_RECRUITING

Cha Bundang Medical Center, Cha University, BundangGu SeongnamSi

13620

NOT_YET_RECRUITING

Seoul National University Bundang Hospital, BundangGu SeongnamSi

21287

RECRUITING

Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

110004

NOT_YET_RECRUITING

Shengjing Hospital of China Medical University, Shenyang

116023

NOT_YET_RECRUITING

The Second Hospital of Dalian Medical University, Dalian

150000

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

200011

NOT_YET_RECRUITING

Obstetrics and Gynecology Hospital of Fudan University, Shanghai

250000

COMPLETED

Qilu Hospital of Shandong University, Jinan

261000

NOT_YET_RECRUITING

Weifang Peoples Hospital, Weifang

272000

NOT_YET_RECRUITING

Affiliated Hospital of Jining Medical University, Jining

300060

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310022

COMPLETED

Zhejiang Cancer Hospital, Hangzhou

350014

NOT_YET_RECRUITING

Fujian Cancer Hospital, Fuzhou

430022

RECRUITING

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

430030

RECRUITING

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan

510060

RECRUITING

Sun Yat Sen University Cancer Center, Guangzhou

710061

SUSPENDED

The First Affiliated Hospital of Xian Jiaotong University, Xi'an

90089-1019

RECRUITING

Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles

80045-2517

RECRUITING

University of Colorado Cancer Center, Aurora

32827-7400

RECRUITING

Florida Cancer Specialist Research Institute Lake Nona, Orlando

43210-1240

RECRUITING

James Cancer Hospital and Solove Research Institute, Columbus

NSW 2109

RECRUITING

Macquarie University, North Ryde

NSW 2500

RECRUITING

Cancer Care Wollongong, Wollongong

QLD 4102

RECRUITING

Princess Alexandra Hospital, Woolloongabba

VIC 3168

RECRUITING

Monash Health, Clayton

VIC 3000

RECRUITING

Peter Maccallum Cancer Centre, Melbourne

WA 6009

RECRUITING

Linear Clinical Research, Nedlands

01246-000

NOT_YET_RECRUITING

Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira, São Paulo

065001

NOT_YET_RECRUITING

Cancer Hospital Chinese Academy of Medical Scienceslangfang Branch, Langfang

06351

NOT_YET_RECRUITING

Samsung Medical Center, GangnamGu

03722

NOT_YET_RECRUITING

Severance Hospital Yonsei University Health System, SeodaemunGu

03080

NOT_YET_RECRUITING

Seoul National University Hospital, Seoul

05505

NOT_YET_RECRUITING

Asan Medical Center, SongpaGu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT06233942 - Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter